Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase III Study Comparing Standard Radiotherapy (24 Gy) With a PET REsponse-guided Very Low Dose (4 Gy) Staged Radiotherapy Strategy for Potentially Curable, Indolent B-cell Lymphomas

NCT07029217 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07029217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07029217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase III Study Comparing Standard Radiotherapy (24 Gy) With a PET REsponse-guided Very Low Dose (4 Gy) Staged Radiotherapy Strategy for Potentially Curable, Indolent B-cell Lymphomas
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 3
Overall status
Recruiting
Start date
June 9, 2025
Completion date
June 30, 2028
Enrollment
375 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, marginal zone lymphoma